FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:375-381 July 28, 2005 Number 4 Next

Summary PDF PDA Full Text PowerPoint Slide Set Editorial by Berger, J. R. Editorial by Drazen, J. M. Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

SUMMARY

We describe the clinical course of a patient with multiple sclerosis in whom progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the central nervous system, developed during treatment with interferon beta-1a and a selective adhesion-molecule blocker, natalizumab. The first PML lesion apparent on magnetic resonance imaging was indistinguishable from a multiple sclerosis lesion. Despite treatment with corticosteroids, cidofovir, and intravenous immune globulin, PML progressed rapidly, rendering the patient quadriparetic, globally aphasic, and minimally responsive. Three months after natalizumab therapy was discontinued, changes consistent with an immune-reconstitution inflammatory syndrome developed. The patient was treated with systemic cytarabine, and two months later, his condition had improved.

We describe the clinical course of a patient with multiple sclerosis in whom PML developed during treatment with interferon beta-1a (Avonex, Biogen Idec) and natalizumab (Tysabri, Biogen Idec and Elan), a monoclonal antibody against ₄ integrins. Despite the discontinuation of these medications, his PML progressed rapidly. An immune-reconstitution inflammatory syndrome developed three months after the cessation of natalizumab therapy, and the patient became bedridden and minimally responsive. Treatment with intravenous cytarabine was begun, and shortly thereafter, his condition improved. The reasons for his clinical deterioration and recovery are not clear.

Case Report

In 1983, a 23-year-old right-handed man had a month-long episode of right hemianesthesia, his first symptom of what proved to be relapsing–remitting multiple sclerosis. He had a second attack in 1989 and had two or three attacks per year between 1989 and 1998. His medical history was also notable for the Ramsay Hunt syndrome with auricular zoster in 1998, a malignant melanoma excised from his back with negative margins in 1996, and a cleft lip and palate. A sister also had relapsing–remitting multiple sclerosis.

He started receiving weekly intramuscular injections of interferon beta-1a in 1998 (Figure 1). The frequency of relapses decreased to one per year until 2001. From 2001 through 2002 he had three exacerbations, prompting his enrollment in a double-blind, randomized, placebo-controlled trial of 300 mg of natalizumab every four weeks plus interferon beta-1a as compared with a placebo infusion plus interferon beta-1a. At entry into the study in October 2002, he had an old left afferent pupillary deficit, mild right lateral rectus palsy, right-sided lower-motor-neuron facial paresis, mild ataxia, a score on the Kurtzke Expanded Disability Status Scale of 2 (scores can range from 0 to 10, with higher scores indicating more severe disease), and evidence of focal, nonenhancing white-matter lesions on T₂-weighted magnetic resonance imaging (MRI) characteristic of multiple sclerosis. During the next two years he had no further relapses. T₂-weighted MRI of the brain, performed as part of the study protocol in October 2003, showed multiple small, nonenhancing periventricular and subcortical hyperintensities consistent with the presence of multiple sclerosis. But in October 2004, in addition to a small, new, enhancing periventricular lesion typical of multiple sclerosis (not shown), a new nonenhancing lesion of the right frontal lobe appeared on another MRI scan obtained as part of the protocol (Figure 2A).

View larger version (21K): [in this window] [in a new window]   Figure 1. Summary of the Patient's Clinical Course, Treatments, and Results of Laboratory Tests. CE denotes contrast enhancement. One upward-pointing arrow indicates a moderate increase, two upward-pointing arrows a substantial increase, and one downward-pointing arrow a moderate decrease.

 

View larger version (75K): [in this window] [in a new window]   Figure 2. Progression of Abnormalities on MRI. Panel A shows images obtained before the development of PML-related symptoms. An axial T2-weighted MRI obtained in October 2003 (left-hand side) shows multiple small focal lesions in the white matter consistent with the presence of multiple sclerosis. In October 2004 (right-hand side), a large, new, ill-defined lesion is seen in the right frontal lobe, which will later prove to be PML. In early February 2005 (Panel B), axial fluid-attenuated inversion recovery MRI (left-hand side) shows more extensive disease in the right frontal white matter, with cortical sparing and several scattered lesions. After the addition of intravenous contrast medium (right-hand side), a few small foci of enhancement are apparent in the right hemisphere. In late March 2005 (Panel C), axial fluid-attenuated inversion recovery MRI (left-hand side) shows dramatic progression, especially in the right hemisphere, with lesions now extending into the anterior corpus callosum. After the addition of intravenous contrast medium (right-hand side), there is a substantial increase in the foci of enhancement.

 
In November 2004, the patient's physician observed uncharacteristic, inappropriate behavior during a routine study visit. In mid-December, the patient told his family and friends that he was having difficulty with attention and concentration. Progressive left hemiparesis, dysarthria, and cognitive impairment subsequently developed. MRI of the brain showed new, extensive abnormalities, including a large hyperintense lesion of the right frontal lobe, bilateral subinsular white-matter lesions that spared the cortex, and scattered lesions in the white matter, deep gray matter, and brain stem, with a few punctate foci of enhancement consistent with the presence of noninflammatory PML¹ (Figure 2B). After receiving 28 infusions, the last in mid-December 2004, the patient stopped taking the study drug, which was revealed to be natalizumab.

The patient was not classically immunocompromised at clinical presentation: he had no known risk factors for HIV infection, serologic analysis for HIV was twice negative, and the total leukocyte count (8.6x10³ per cubic millimeter) and values for lymphocyte subgroups were normal (CD4:CD8 ratio, 1.1; CD4 T-cell count, 637 per cubic millimeter; and CD8 T-cell count, 564 per cubic millimeter). Analysis of cerebrospinal fluid in early February showed no white cells and 88 red cells per cubic millimeter, normal cytologic findings, and normal concentrations of both total protein (41 mg per deciliter) and glucose (62 mg per deciliter [3.4 mmol per liter]). The IgG index (a measure of the IgG production in the cerebrospinal fluid) was elevated (0.7), and two oligoclonal bands were seen. JC virus DNA was detected by the polymerase chain reaction (PCR)² in the serum (2500 copies per milliliter), peripheral-blood mononuclear cells (225 copies per milliliter), and cerebrospinal fluid (6050 copies per milliliter). Biopsy of the right frontal lobe showed abundant areas of astrogliosis and microgliosis in the deep layers of cortical gray matter, with underlying white matter showing demyelination, dense infiltration of macrophages, and sparse lymphocytes. Scattered enlarged oligodendrocytes contained intranuclear inclusions positive for papovavirus (Figure 3). In situ hybridization showed JC virus but no evidence of herpes simplex virus or cytomegalovirus. A workup for cancer, including computed tomography (CT) of the chest, abdomen, and pelvis and whole-body positron-emission tomography, showed no masses and no areas of increased metabolism. Positron-emission tomography did show decreased cortical uptake of fludeoxyglucose F 18 within the right frontal lobe, a finding consistent with necrosis.

View larger version (78K): [in this window] [in a new window]   Figure 3. Brain-Biopsy Specimen. Panel A shows a focus of demyelination (hematoxylin and eosin), and Panel B immunohistochemical staining for papovavirus.

 
During the next three weeks, left hemiplegia, left-sided neglect, left hemianesthesia, apraxia of the right arm, and nonfluent aphasia developed and dysarthria worsened despite intravenous treatment with high-dose methylprednisolone. Intravenous treatment with cidofovir (5 mg per kilogram of body weight every two weeks) was initiated.

Eight days later, global aphasia, incontinence, stooped posture, and truncal instability developed. Repeated analysis of cerebrospinal fluid showed a mild pleocytosis and hemorrhage: an elevated protein concentration (58 mg per deciliter), 2 white cells and 324 red cells in the second tube obtained, and 6 white cells (30 percent neutrophils, 55 percent lymphocytes, 4 percent reactive lymphocytes, and 11 percent monocytoid cells) and 913 red cells in the subsequent tube. JC virus DNA was undetectable in peripheral-blood mononuclear cells and plasma but remained present in the cerebrospinal fluid (2245 copies per milliliter). PCR of cerebrospinal fluid for herpes simplex virus, human herpesvirus 6, varicella–zoster virus, Epstein–Barr virus, and enteroviruses was negative, as were the results of Gram's staining, bacterial culture, cryptococcal staining, staining for acid-fast bacilli, and serologic analysis for Lyme disease. CT of the head showed no evidence of hemorrhage. MRI of the brain five weeks later (Figure 2C) showed marked progression of the white- and gray-matter lesions and extensive foci of enhancement, particularly in the right hemisphere, findings consistent with inflammation.

The patient's hospital course was further complicated by methicillin-resistant Staphylococcus aureus bacteremia, urosepsis, upper gastrointestinal bleeding, elevated concentrations of serum aminotransferases, transient hyponatremia, and transient lymphopenia. The nadir absolute lymphocyte count was 647 cells per cubic millimeter, with 188 CD4+ T cells per cubic millimeter, 214 CD8+ T cells per cubic millimeter, and a CD4:CD8 ratio of 0.9.

His condition continued to deteriorate, despite the administration of three infusions of cidofovir over a period of eight weeks and a five-day course of intravenous immune globulin (2 g per kilogram per day). Left hemiplegia, anesthesia, and neglect were now accompanied by right hemiparesis and apraxia, nonfluent aphasia, severe cognitive impairment, and a fluctuating level of alertness, rendering the patient bedridden, mute, and almost completely noncommunicative. Electroencephalography at this time showed diffuse slowing and bilateral periodic epileptiform discharges that did not respond to treatment with intravenous benzodiazepam.

His treating physicians began intravenous treatment with cytarabine (2 mg per kilogram per day for five days) in early April. This caused pancytopenia, requiring the administration of erythropoietin and granulocyte colony-stimulating factor, and fever; the latter resolved within 12 hours after empirical antibiotic treatment.

Unexpectedly, the patient began talking two weeks after the initiation of cytarabine therapy. At the time of the most recent follow-up assessment, he continued to show neurologic improvement. After one month of cytarabine therapy, his right-sided weakness and left-sided sensory loss resolved, and his left hemiplegia, neglect, aphasia, and dysarthria began to improve. He still had severe deficits, including dysarthria, spastic left hemiparesis, cognitive impairment, and parkinsonism. He required the assistance of two persons to move from a bed to a chair. MRI of the brain obtained three weeks after treatment with cytarabine was begun showed further progression of disease in the left cerebellar white matter, right external and internal capsule, and frontal lobes bilaterally. The only detectable improvement was a slight decrease in the amount of contrast enhancement.

A second course of cytarabine was given four weeks after the first, without any complications. By the end of May 2005, the patient was starting to walk and was having meaningful conversations regarding the reasons for his clinical deterioration. He still had disabling ataxia, cognitive impairment, mild neglect, and mild left hemiparesis.

Discussion

Our patient is one of three patients in whom rapidly progressive PML has been shown to develop during clinical trials of natalizumab, a selective adhesion-molecule blocker, to treat relapsing–remitting multiple sclerosis or Crohn's disease.^3,4,5 Elsewhere in this issue of the Journal, Kleinschmidt-DeMasters and Tyler describe a second patient with multiple sclerosis who received combination treatment with natalizumab and interferon beta-1a³ and Van Assche et al. describe a patient with Crohn's disease who received natalizumab alone.⁴

Our patient's condition worsened after the cessation of natalizumab therapy despite treatment with cidofovir, corticosteroids, and intravenous immune globulin, but his condition improved after the institution of systemic cytarabine therapy. His brain biopsy showed typical noninflammatory PML; however, three months after the cessation of natalizumab, what we believe to be an immune-reconstitution inflammatory syndrome developed that was characterized by widespread inflammation of the central nervous system, as shown by extensive enhancement on MRI and microscopic hemorrhages. Other remarkable features of the case include JC virus viremia and MRI evidence of PML one month before symptoms developed.

JC virus is a ubiquitous infection acquired in childhood that remains dormant in bone marrow, kidney epithelia, and spleen. Antibodies against JC virus are detectable in at least 80 percent of adults.⁶ However, humoral immunity is insufficient to prevent the spread of the virus to the central nervous system. Intermittent reactivation, with shedding of live virus in the urine, has been well documented in cross-sectional studies of healthy adults and pregnant women, but this phenomenon is poorly understood. Spread of the virus to the central nervous system and the subsequent development of PML occur in immunocompromised persons — most commonly those infected with HIV, but also in some patients with lymphoma, sarcoidosis, and medication-induced immunosuppression. JC virus can enter the central nervous system directly during periods of viremia, such as those occurring during prolonged immunosuppression. Eighty to 90 percent of patients with PML but not HIV infection die within one year.⁷

Natalizumab is highly effective at preventing recurrent inflammation in patients with multiple sclerosis.⁸ Natalizumab binds to and blocks the function of ₄ integrins, adhesion molecules that promote the migration of lymphocytes into various organs, including the brain⁹ and kidneys.¹⁰ In patients with multiple sclerosis, natalizumab's most striking effect is the reduction of both contrast-enhancing lesions on MRI and clinical relapses.⁸

How natalizumab therapy alone or in combination with other immune-altering therapies could lead to JC virus viremia and PML is unknown. We speculate that the reactivation of the virus cannot be suppressed until the effects of natalizumab wear off. In our patient, JC virus viremia ended three months after treatment with natalizumab was stopped, and the biologic effects of natalizumab have been shown to wear off after about three months.¹¹

Three months after natalizumab therapy was stopped, an inflammatory reaction developed in our patient's brain. In HIV-infected patients, as in our patient, inflammatory reactions against PML are a manifestation of the immune-reconstitution inflammatory syndrome and are associated with clinical deterioration and increases in the size of high signal lesions on T₂-weighted MRI but more favorable outcomes than in noninflammatory PML.^12,13 However, patients can die during the course of the immune-reconstitution inflammatory syndrome,¹³ as our patient almost did, and how best to manage the JC virus infection and this inflammatory phase of PML is unknown.

Cidofovir, an antiviral agent, has been used with anecdotal success in the treatment of HIV-associated PML.^14,15 However, in vitro, cidofovir fails to kill glial cells infected with JC virus,¹⁶ and there are no controlled studies to support its use. After three courses of cidofovir, our patient's condition continued to deteriorate.

Cytarabine kills JC virus in vitro.¹⁶ This observation led to a randomized, controlled trial of the drug in HIV-infected patients with PML, which failed to show efficacy.¹⁷ However, the penetration of cytarabine into the central nervous system is poor, and only one patient in this trial had contrast enhancement on MRI.¹⁸ We chose to administer cytarabine to our patient, given the failure of cidofovir and the lack of other options, and subsequently, his condition improved. The reasons for this improvement are not clear. It is possible that the extensive breakdown of his blood–brain barrier improved penetration of cytarabine into the central nervous system, aiding in the clearance of the virus, or that its strong myelosuppressive properties curbed the inflammatory response. Alternatively, the improvement may have been due solely to clearance of the virus by the patient's reconstituted immune system.

In our patient, the first PML lesion — a frontal-lobe lesion that was indistinguishable from a multiple sclerosis lesion — was visible on neuroimaging studies two months before obvious neurologic deficits developed. Although this may be due to the relatively subtle deficits that would be expected as a result of a lesion in this area, it suggests that more frequent MRI monitoring of patients who receive natalizumab may be warranted. The appearance of lesions, particularly in or abutting the gray matter, should increase clinical suspicion of PML. Monitoring for JC virus viremia may also be useful in such patients. Our case report suggests that some degree of recovery from natalizumab-associated PML is possible.

Supported by a grant (NS43207-03) from the National Institute of Neurological Diseases and Stroke and a Wadsworth Foundation Young Investigators Award (both to Dr. Langer-Gould).

Dr. Langer-Gould reports having received consulting and lecture fees from Biogen Idec; and Dr. Pelletier, consulting fees, lecture fees, and grant support from Biogen Idec.

We are indebted to Kristin Cobb and Michael K. Gould for helpful reviews of the manuscript, to Caroline Ryschkewitsch and Eugene Major for determining the JC virus titers to Mary Owen, Heather Hinds, Keith K. Abe, and Jeffrey H. Gertsch for their outstanding clinical care of the patient, and to the patient and his family for allowing us to report his story.

Source Information

From the Departments of Neurology and Health Research and Policy, Stanford University School of Medicine, Stanford, Calif. (A.L.-G.); the Department of Radiology, Hoover Institution at Stanford University, Stanford, Calif. (S.W.A.); and the Departments of Pathology (A.W.B.) and Neurology (A.J.G., D.P.), University of California, San Francisco, San Francisco.

This article was published at www.nejm.org on June 9, 2005.

Address reprint requests to Dr. Annette Langer-Gould at HRP Redwood Bldg., Rm. T202, Stanford, CA 94305-5405, or at annette1{at}stanford.edu.

References

1. Mark AS, Atlas SW. Progressive multifocal leukoencephalopathy in patients with AIDS: appearance on MR images. Radiology 1989;173:517-520. [Free Full Text]
2. Ryschkewitsch C, Jensen P, Hou J, Fahle G, Fischer S, Major EO. Comparison of PCR-southern hybridization and quantitative real-time PCR for the detection of JCV and BK viral nucleotide sequences in urine and cerebrospinal fluids. J Virol Methods 2004;121:217-221. [Medline]
3. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005;353:369-374. [Free Full Text]
4. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005;353:362-368. [Free Full Text]
5. Calabresi P. Safety and tolerability of natalizumab: results from the SENTINEL Trial. Presented at the American Academy of Neurology 57th Annual Meeting, Miami Beach, Fla., April 9–16, 2005. abstract.
6. Padgett BL, Walker DL. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis 1973;127:467-470. [Web of Science][Medline]
7. Brooks BR, Walker DL. Progressive multifocal leukoencephalopathy. Neurol Clin 1984;2:299-313. [Web of Science][Medline]
8. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23. [Free Full Text]
9. von Andrian UH, Engelhardt B. ₄ Integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003;348:68-72. [Free Full Text]
10. Escudero E, Nieto M, Martin A, et al. Differential effects of antibodies to vascular cell adhesion molecule-1 and distinct epitopes of the alpha4 integrin in HgCl2-induced nephritis in Brown Norway rats. J Am Soc Nephrol 1998;9:1881-1891. [Abstract]
11. Tubridy N, Behan PO, Capildeo R, et al. The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. Neurology 1999;53:466-472. [Free Full Text]
12. Du Pasquier RA, Koralnik IJ. Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol 2003;9:Suppl 1:25-31.
13. Cinque P, Bossolasco S, Brambilla AM, et al. The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol 2003;9:Suppl 1:73-80.
14. De Luca A, Giancola ML, Ammassari A, et al. Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: extended follow-up of an observational study. J Neurovirol 2001;7:364-368. [CrossRef][Medline]
15. Gasnault J, Kousignian P, Kahraman M, et al. Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: a monocenter observational study with clinical and JC virus load monitoring. J Neurovirol 2001;7:375-381. [CrossRef][Web of Science][Medline]
16. Hou J, Major EO. The efficacy of nucleoside analogs against JC virus multiplication in a persistently infected human fetal brain cell line. J Neurovirol 1998;4:451-456. [Web of Science][Medline]
17. Hall CD, Dafni U, Simpson D, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. N Engl J Med 1998;338:1345-1351. [Free Full Text]
18. Post MJ, Yiannoutsos C, Simpson D, et al. Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AJNR Am J Neuroradiol 1999;20:1896-1906. [Free Full Text]

Summary PDF PDA Full Text PowerPoint Slide Set Editorial by Berger, J. R. Editorial by Drazen, J. M. Letters Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Related Letters:

Progressive Multifocal Leukoencephalopathy, Natalizumab, and Multiple Sclerosis
Berger T., Deisenhammer F., Álvarez-Cermeño J. C., Masjuan J., Villar L. M., Kleinschmidt-DeMasters B.K., Tyler K. L., Langer-Gould A., Atlas S. W., Pelletier D.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:1744-1746, Oct 20, 2005. Correspondence

Natalizumab and Progressive Multifocal Leukoencephalopathy
Adelman B., Sandrock A., Panzara M. A.
Extract | Full Text | PDF  
N Engl J Med 2005; 353:432-433, Jul 28, 2005; published at www.nejm.org on Jun 9, 2005 (10.1056/NEJMc055235). Correspondence

This article has been cited by other articles:

• Rinaldi, F., Perini, P., Calabrese, M., Rinaldi, L., Gallo, P. (2009). Severe relapses after the first infusion of natalizumab in active relapsing--remitting multiple sclerosis. Mult Scler 15: 1359-1362 [Abstract]  
• Stuve, O., Wiendl, H. (2009). Iatrogenic immunosuppression with biologics in MS: Expecting the unexpected?. Neurology 73: 1346-1347 [Full Text]  
• De Serres, S. A., Sayegh, M. H., Najafian, N. (2009). Immunosuppressive Drugs and Tregs: A Critical Evaluation!. CJASN 4: 1661-1669 [Abstract] [Full Text]  
• Chen, Y., Bord, E., Tompkins, T., Miller, J., Tan, C. S., Kinkel, R. P., Stein, M. C., Viscidi, R. P., Ngo, L. H., Koralnik, I. J. (2009). Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab. NEJM 361: 1067-1074 [Abstract] [Full Text]  
• Wenning, W., Haghikia, A., Laubenberger, J., Clifford, D. B., Behrens, P. F., Chan, A., Gold, R. (2009). Treatment of Progressive Multifocal Leukoencephalopathy Associated with Natalizumab. NEJM 361: 1075-1080 [Abstract] [Full Text]  
• Linda, H., von Heijne, A., Major, E. O., Ryschkewitsch, C., Berg, J., Olsson, T., Martin, C. (2009). Progressive Multifocal Leukoencephalopathy after Natalizumab Monotherapy. NEJM 361: 1081-1087 [Abstract] [Full Text]  
• Soler, D., Chapman, T., Yang, L.-L., Wyant, T., Egan, R., Fedyk, E. R. (2009). The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti-{alpha}4{beta}7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases. J. Pharmacol. Exp. Ther. 330: 864-875 [Abstract] [Full Text]  
• Tyler, K. L. (2009). Emerging Viral Infections of the Central Nervous System: Part 2. Arch Neurol 66: 1065-1074 [Abstract] [Full Text]  
• Korman, B. D., Tyler, K. L., Korman, N. J. (2009). Progressive Multifocal Leukoencephalopathy, Efalizumab, and Immunosuppression: A Cautionary Tale for Dermatologists. Arch Dermatol 145: 937-942 [Full Text]  
• Helliwell, C. L., Coles, A. J. (2009). Monoclonal antibodies in multiple sclerosis treatment: current and future steps. Therapeutic Advances in Neurological Disorders 2: 195-203  
• Kivisakk, P., Healy, B. C., Viglietta, V., Quintana, F. J., Hootstein, M. A., Weiner, H. L., Khoury, S. J. (2009). Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 72: 1922-1930 [Abstract] [Full Text]  
• Carson, K. R., Evens, A. M., Richey, E. A., Habermann, T. M., Focosi, D., Seymour, J. F., Laubach, J., Bawn, S. D., Gordon, L. I., Winter, J. N., Furman, R. R., Vose, J. M., Zelenetz, A. D., Mamtani, R., Raisch, D. W., Dorshimer, G. W., Rosen, S. T., Muro, K., Gottardi-Littell, N. R., Talley, R. L., Sartor, O., Green, D., Major, E. O., Bennett, C. L. (2009). Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113: 4834-4840 [Abstract] [Full Text]  
• Khanna, N., Wolbers, M., Mueller, N. J., Garzoni, C., Du Pasquier, R. A., Fux, C. A., Vernazza, P., Bernasconi, E., Viscidi, R., Battegay, M., Hirsch, H. H., for the Swiss HIV Cohort Study, (2009). JC Virus-Specific Immune Responses in Human Immunodeficiency Virus Type 1 Patients with Progressive Multifocal Leukoencephalopathy. J. Virol. 83: 4404-4411 [Abstract] [Full Text]  
• Boster, A., Hreha, S., Berger, J. R., Bao, F., Penmesta, R., Tselis, A., Endress, C., Zak, I., Perumal, J., Caon, C., Vazquez, J., Tyler, K. L., Racke, M. K., Millis, S., Khan, O. (2009). Progressive Multifocal Leukoencephalopathy and Relapsing-Remitting Multiple Sclerosis: A Comparative Study. Arch Neurol 66: 593-599 [Abstract] [Full Text]  
• Bomback, A. S., Derebail, V. K., McGregor, J. G., Kshirsagar, A. V., Falk, R. J., Nachman, P. H. (2009). Rituximab Therapy for Membranous Nephropathy: A Systematic Review. CJASN 4: 734-744 [Abstract] [Full Text]  
• Yaldizli, O., Putzki, N. (2009). Review: Natalizumab in the treatment of multiple sclerosis. Therapeutic Advances in Neurological Disorders 2: 115-128 [Abstract]  
• Cohen, J. A., Imrey, P. B., Calabresi, P. A., Edwards, K. R., Eickenhorst, T., Felton, W. L. III, Fisher, E., Fox, R. J., Goodman, A. D., Hara-Cleaver, C., Hutton, G. J., Mandell, B. F., Scott, T. F., Zhang, H., Apperson-Hansen, C., Beck, G. J., Houghtaling, P. L., Karafa, M. T., Stadtler, M., For the ACT Investigators, (2009). Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology 72: 535-541 [Abstract] [Full Text]  
• Khatri, B. O., Man, S., Giovannoni, G., Koo, A. P., Lee, J-C, Tucky, B., Lynn, F., Jurgensen, S., Woodworth, J., Goelz, S., Duda, P. W., Panzara, M. A., Ransohoff, R. M., Fox, R. J. (2009). Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72: 402-409 [Abstract] [Full Text]  
• Stuve, O., Cravens, P. D., Frohman, E. M., Phillips, J. T., Remington, G. M., von Geldern, G., Cepok, S., Singh, M. P., Cohen Tervaert, J. W., De Baets, M., MacManus, D., Miller, D. H., Radu, E. W., Cameron, E. M., Monson, N. L., Zhang, S., Kim, R., Hemmer, B., Racke, M. K. (2009). Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 72: 396-401 [Abstract] [Full Text]  
• Iacobaeus, E, Ryschkewitsch, C, Gravell, M, Khademi, M, Wallstrom, E, Olsson, T, Brundin, L, Major, E. (2009). Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA. Mult Scler 15: 28-35 [Abstract]  
• Martin, M. d. P., Cravens, P. D., Winger, R., Frohman, E. M., Racke, M. K., Eagar, T. N., Zamvil, S. S., Weber, M. S., Hemmer, B., Karandikar, N. J., Kleinschmidt-DeMasters, B. K., Stuve, O. (2008). Decrease in the Numbers of Dendritic Cells and CD4+ T Cells in Cerebral Perivascular Spaces Due to Natalizumab. Arch Neurol 65: 1596-1603 [Abstract] [Full Text]  
• Shprecher, D, Frech, T, Chin, S, Eskandari, R, Steffens, J (2008). Progressive multifocal leucoencephalopathy associated with lupus and methotrexate overdose. Lupus 17: 1029-1032 [Abstract]  
• Clifford, D. B (2008). Natalizumab and PML: a risky business?. Gut 57: 1347-1349 [Full Text]  
• Verbeeck, J, Van Assche, G, Ryding, J, Wollants, E, Rans, K, Vermeire, S, Pourkarim, M R, Noman, M, Dillner, J, Van Ranst, M, Rutgeerts, P (2008). JC viral loads in patients with Crohn's disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?. Gut 57: 1393-1397 [Abstract] [Full Text]  
• Goodin, D. S., Cohen, B. A., O'Connor, P., Kappos, L., Stevens, J. C. (2008). Assessment: The use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 71: 766-773 [Abstract] [Full Text]  
• Schaumburg, C., O'Hara, B. A., Lane, T. E., Atwood, W. J. (2008). Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cells Express the Serotonin Receptor and Are Susceptible to JC Virus Infection. J. Virol. 82: 8896-8899 [Abstract] [Full Text]  
• Thompson, J. P., Noyes, K., Dorsey, E. R., Schwid, S. R., Holloway, R. G. (2008). Quantitative risk-benefit analysis of natalizumab. Neurology 71: 357-364 [Abstract] [Full Text]  
• Linker, R. A., Kieseier, B. C. (2008). Review: Innovative monoclonal antibody therapies in multiple sclerosis. Therapeutic Advances in Neurological Disorders 1: 33-42 [Abstract]  
• Takabe, K., Paugh, S. W., Milstien, S., Spiegel, S. (2008). "Inside-Out" Signaling of Sphingosine-1-Phosphate: Therapeutic Targets. Pharmacol. Rev. 60: 181-195 [Abstract] [Full Text]  
• Merabova, N., Kaniowska, D., Kaminski, R., Deshmane, S. L., White, M. K., Amini, S., Darbinyan, A., Khalili, K. (2008). JC Virus Agnoprotein Inhibits In Vitro Differentiation of Oligodendrocytes and Promotes Apoptosis. J. Virol. 82: 1558-1569 [Abstract] [Full Text]  
• O'Rourke, A. M., Wang, E. Y., Miller, A., Podar, E. M., Scheyhing, K., Huang, L., Kessler, C., Gao, H., Ton-Nu, H.-T., MacDonald, M. T., Jones, D. S., Linnik, M. D. (2008). Anti-Inflammatory Effects of LJP 1586 [Z-3-Fluoro-2-(4-methoxybenzyl)allylamine Hydrochloride], an Amine-Based Inhibitor of Semicarbazide-Sensitive Amine Oxidase Activity. J. Pharmacol. Exp. Ther. 324: 867-875 [Abstract] [Full Text]  
• Brown, B. A, Kantesaria, P. P, McDevitt, L. M (2007). Fingolimod: A Novel Immunosuppressant for Multiple Sclerosis. The Annals of Pharmacotherapy 41: 1660-1668 [Abstract] [Full Text]  
• Kobayashi, N., Kobayashi, H., Gu, L., Malefyt, T., Siahaan, T. J. (2007). Antigen-Specific Suppression of Experimental Autoimmune Encephalomyelitis by a Novel Bifunctional Peptide Inhibitor. J. Pharmacol. Exp. Ther. 322: 879-886 [Abstract] [Full Text]  
• Robinson, M. R., Korman, B. D., Korman, N. J. (2007). Combination Immunosuppressive Therapies: The Promise and the Peril. Arch Dermatol 143: 1053-1057 [Abstract] [Full Text]  
• Alvarez-Lafuente, R., Garcia-Montojo, M., De Las Heras, V., Bartolome, M., Arroyo, R. (2007). JC virus in cerebrospinal fluid samples of multiple sclerosis patients at the first demyelinating event. Mult Scler 13: 590-595 [Abstract]  
• Bullard, D. C., Hu, X., Adams, J. E., Schoeb, T. R., Barnum, S. R. (2007). p150/95 (CD11c/CD18) Expression Is Required for the Development of Experimental Autoimmune Encephalomyelitis. Am. J. Pathol. 170: 2001-2008 [Abstract] [Full Text]  
• D'Haens, G. (2007). Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 56: 725-732 [Full Text]  
• Balcer, L. J., Galetta, S. L., Calabresi, P. A., Confavreux, C., Giovannoni, G., Havrdova, E., Hutchinson, M., Kappos, L., Lublin, F. D., Miller, D. H., O'Connor, P. W., Phillips, J. T., Polman, C. H., Radue, E. -W., Rudick, R. A., Stuart, W. H., Wajgt, A., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A., for the AFFIRM and SENTINEL Investigators, (2007). Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology 68: 1299-1304 [Abstract] [Full Text]  
• Allander, T., Andreasson, K., Gupta, S., Bjerkner, A., Bogdanovic, G., Persson, M. A. A., Dalianis, T., Ramqvist, T., Andersson, B. (2007). Identification of a Third Human Polyomavirus. J. Virol. 81: 4130-4136 [Abstract] [Full Text]  
• Sweet, B. V. (2007). Natalizumab update. Am J Health Syst Pharm 64: 705-716 [Abstract] [Full Text]  
• Choudry, B. A., Chan, J. W. (2007). An Update on Monoclonal Antibody Therapies in Multiple Sclerosis. Journal of Pharmacy Practice 20: 167-180 [Abstract]  
• Lima, M. A., Marzocchetti, A., Autissier, P., Tompkins, T., Chen, Y., Gordon, J., Clifford, D. B., Gandhi, R. T., Venna, N., Berger, J. R., Koralnik, I. J. (2007). Frequency and Phenotype of JC Virus-Specific CD8+ T Lymphocytes in the Peripheral Blood of Patients with Progressive Multifocal Leukoencephalopathy. J. Virol. 81: 3361-3368 [Abstract] [Full Text]  
• Khalili, K., White, M. K., Lublin, F., Ferrante, P., Berger, J. R. (2007). Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology 68: 985-990 [Abstract] [Full Text]  
• Stuve, O., Marra, C. M., Cravens, P. D., Singh, M. P., Hu, W., Lovett-Racke, A., Monson, N. L., Phillips, J. T., Tervaert, J. W. C., Nash, R. A., Hartung, H.-P., Kieseier, B. C., Racke, M. M., Frohman, E. M., Hemmer, B. (2007). Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab Therapy: Possible Interventions. Arch Neurol 64: 169-176 [Abstract] [Full Text]  
• Samuels, M. A. (2007). Update in Neurology. ANN INTERN MED 146: 128-132 [Full Text]  
• Johnston, S. L (2007). Biologic therapies: what and when?. J. Clin. Pathol. 60: 8-17 [Abstract] [Full Text]  
• Manley, K., O'Hara, B. A., Gee, G. V., Simkevich, C. P., Sedivy, J. M., Atwood, W. J. (2006). NFAT4 Is Required for JC Virus Infection of Glial Cells. J. Virol. 80: 12079-12085 [Abstract] [Full Text]  
• Langer-Gould, A., Popat, R. A., Huang, S. M., Cobb, K., Fontoura, P., Gould, M. K., Nelson, L. M. (2006). Clinical and Demographic Predictors of Long-term Disability in Patients With Relapsing-Remitting Multiple Sclerosis: A Systematic Review. Arch Neurol 63: 1686-1691 [Abstract] [Full Text]  
• Berger, J R (2006). Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis 65: iii48-iii53 [Abstract] [Full Text]  
• Querbes, W., O'Hara, B. A., Williams, G., Atwood, W. J. (2006). Invasion of Host Cells by JC Virus Identifies a Novel Role for Caveolae in Endosomal Sorting of Noncaveolar Ligands. J. Virol. 80: 9402-9413 [Abstract] [Full Text]  
• Stuve, O., Marra, C. M., Bar-Or, A., Niino, M., Cravens, P. D., Cepok, S., Frohman, E. M., Phillips, J. T., Arendt, G., Jerome, K. R., Cook, L., Grand'Maison, F., Hemmer, B., Monson, N. L., Racke, M. K. (2006). Altered CD4+/CD8+ T-Cell Ratios in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.. Arch Neurol 63: 1383-1387 [Abstract] [Full Text]  
• Eng, P. M., Turnbull, B. R., Cook, S. F., Davidson, J. E., Kurth, T., Seeger, J. D. (2006). Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population.. Neurology 67: 884-886 [Abstract] [Full Text]  
• Franciotta, D., Bestetti, A., Bergamaschi, R., Piccolo, G., Persico, A., Cinque, P. (2006). Letter to the Editor. Mult Scler 12: 674-675  
• del Zoppo, G. J., Milner, R. (2006). Integrin-Matrix Interactions in the Cerebral Microvasculature. Arterioscler. Thromb. Vasc. Bio. 26: 1966-1975 [Abstract] [Full Text]  
• Friese, M. A., Montalban, X., Willcox, N., Bell, J. I., Martin, R., Fugger, L. (2006). The value of animal models for drug development in multiple sclerosis. Brain 129: 1940-1952 [Abstract] [Full Text]  
• Skromne, E., Rivera, V. M., Ontaneda, D., Ordonez, L., Nath, A., Venkataramana, A., Riech, D. S., Cortese, I., Major, E. O. (2006). Progression of progressive multifocal leukoencephalopathy despite treatment with {beta}-interferon. Neurology 66: 1787-1788 [Full Text]  
• Kerfoot, S. M., Norman, M. U., Lapointe, B. M., Bonder, C. S., Zbytnuik, L., Kubes, P. (2006). Reevaluation of P-Selectin and {alpha}4 Integrin as Targets for the Treatment of Experimental Autoimmune Encephalomyelitis. J. Immunol. 176: 6225-6234 [Abstract] [Full Text]  
• Huang, D., Shi, F.-D., Jung, S., Pien, G. C., Wang, J., Salazar-Mather, T. P., He, T. T., Weaver, J. T., Ljunggren, H.-G., Biron, C. A., Littman, D. R., Ransohoff, R. M. (2006). The neuronal chemokine CX3CL1/fractalkine selectively recruits NK cells that modify experimental autoimmune encephalomyelitis within the central nervous system. FASEB J. 20: 896-905 [Abstract] [Full Text]  
• Chen, Y., Trofe, J., Gordon, J., Du Pasquier, R. A., Roy-Chaudhury, P., Kuroda, M. J., Woodle, E. S., Khalili, K., Koralnik, I. J. (2006). Interplay of Cellular and Humoral Immune Responses against BK Virus in Kidney Transplant Recipients with Polyomavirus Nephropathy.. J. Virol. 80: 3495-3505 [Abstract] [Full Text]  
• Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., Toal, M., Lynn, F., Panzara, M. A., Sandrock, A. W., the AFFIRM Investigators, (2006). A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.. NEJM 354: 899-910 [Abstract] [Full Text]  
• Rudick, R. A., Stuart, W. H., Calabresi, P. A., Confavreux, C., Galetta, S. L., Radue, E.-W., Lublin, F. D., Weinstock-Guttman, B., Wynn, D. R., Lynn, F., Panzara, M. A., Sandrock, A. W., the SENTINEL Investigators, (2006). Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.. NEJM 354: 911-923 [Abstract] [Full Text]  
• Yousry, T. A., Major, E. O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Miszkiel, K., Mueller-Lenke, N., Sanchez, E., Barkhof, F., Radue, E.-W., Jager, H. R., Clifford, D. B. (2006). Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.. NEJM 354: 924-933 [Abstract] [Full Text]  
• Frohman, E. M., Racke, M. K., Raine, C. S. (2006). Multiple sclerosis--the plaque and its pathogenesis.. NEJM 354: 942-955 [Full Text]  
• Ropper, A. H. (2006). Selective treatment of multiple sclerosis.. NEJM 354: 965-967 [Full Text]  
• Chaudhuri, A. (2006). Lessons for clinical trials from natalizumab in multiple sclerosis.. BMJ 332: 416-419 [Full Text]  
• Hoffman, J. M., Shah, N. D., Vermeulen, L. C., Schumock, G. T., Grim, P., Hunkler, R. J., Hontz, K. M. (2006). Projecting future drug expenditures--2006. Am J Health Syst Pharm 63: 123-138 [Abstract] [Full Text]  
• Sandborn, W. J., Colombel, J. F., Enns, R., Feagan, B. G., Hanauer, S. B., Lawrance, I. C., Panaccione, R., Sanders, M., Schreiber, S., Targan, S., van Deventer, S., Goldblum, R., Despain, D., Hogge, G. S., Rutgeerts, P., the International Efficacy of Natalizumab as Activ, (2005). Natalizumab induction and maintenance therapy for Crohn's disease.. NEJM 353: 1912-1925 [Abstract] [Full Text]  
• Podolsky, D. K. (2005). Selective adhesion-molecule therapy and inflammatory bowel disease -- a tale of janus?. NEJM 353: 1965-1968 [Full Text]  
• Keeley, K. A, Rivey, M. P, Allington, D. R (2005). Natalizumab for the Treatment of Multiple Sclerosis and Crohn's Disease. The Annals of Pharmacotherapy 39: 1833-1843 [Abstract] [Full Text]  
• Weinblatt, M E (2005). Will our current success in treating rheumatoid arthritis hinder new drug development? That is the question!!. Ann Rheum Dis 64: 1529-1531 [Full Text]  
• Berger, T., Deisenhammer, F., Alvarez-Cermeno, J. C., Masjuan, J., Villar, L. M., Kleinschmidt-DeMasters, B.K., Tyler, K. L., Langer-Gould, A., Atlas, S. W., Pelletier, D. (2005). Progressive multifocal leukoencephalopathy, natalizumab, and multiple sclerosis.. NEJM 353: 1744-1746 [Full Text]  
• (2005). PML in Patients Receiving Natalizumab. JWatch Infect. Diseases 2005: 1-1 [Full Text]  
• Berger, J. R., Koralnik, I. J. (2005). Progressive Multifocal Leukoencephalopathy and Natalizumab -- Unforeseen Consequences. NEJM 353: 414-416 [Full Text]  
• Drazen, J. M. (2005). Patients at Risk. NEJM 353: 417-417 [Full Text]  
• Adelman, B., Sandrock, A., Panzara, M. A. (2005). Natalizumab and Progressive Multifocal Leukoencephalopathy. NEJM 353: 432-433 [Full Text]